Rani Therapeutics Holdings (NASDAQ: RANI) has announced a research and development collaboration with PegBio (SEHK: 2565) to explore the delivery of multiple novel candidates from PegBio’s obesity and metabolic disease pipeline using Rani’s proprietary RaniPill platform.
Under the terms of the agreement, Rani and PegBio will collaborate on the preclinical development of RaniPill formulations for multiple molecules selected from PegBio’s obesity and metabolic disease portfolio, with the goal of advancing the most promising candidates into clinical development.
In a statement, Talat Imran, CEO of Rani, commented, “This collaboration with PegBio is an important step in our strategy to broaden and diversify our obesity franchise across multiple mechanisms of action. Expanding our collaborations across multiple candidates further reflects our confidence in the versatility of the RaniPill and our commitment to giving patients more oral options. PegBio’s pipeline is aligned with where we see the greatest unmet need and market potential in obesity.”
Michael Xu, CEO of PegBio, added, “The RaniPill platform is uniquely positioned to unlock the full potential of PegBio’s molecules by delivering them orally and we look forward to working together to advance the development of these programs.”
